logo
Apple quietens Wall Street's fears of China struggles and slow AI progress

Apple quietens Wall Street's fears of China struggles and slow AI progress

Yahoo5 days ago
Apple has been under pressure this year. It's playing catch-up to its fellow tech giants on artificial intelligence, it's seen its stock fall by double digits since the year began, it closed a store in China for the first time ever this week, and looming US tariffs on Beijing threaten its supply chain. On Thursday, the company released its third-quarter earnings of the fiscal year as investors scrutinize how the iPhone maker might turn things around.
Despite the gloomy outlook, the company is still worth more than $3tn, and it beat Wall Street's expectations for profit and revenue this quarter. Apple reported a massive 10% year-over-year increase in revenue to $94.04bn, and $1.57 per share in earnings. That's substantially more than the $89.3bn in revenue and $1.43 per share that analysts predicted and is the company's biggest revenue growth since 2021.
Apple's iPhone revenue also outperformed Wall Street's expectations, coming in 13% higher than the same time last year.
Tim Cook, Apple's chief executive, said in a statement that the company was 'proud' to report a 'June quarter revenue record', showing growth in its iPhone, Mac and services divisions. On an earnings call on Thursday, he said the quarterly results were 'better than we expected'.
Dipanjan Chatterjee, a vice-president and principal analyst for Forrester, said rising services tend to boost the company's revenue stream. 'Apple has grown accustomed to having revenue growth in this high-margin services business, which masks other areas of the business not performing as well,' Chatterjee explained .
He pointed to several issues that have led to Apple's less-than-stellar product performance of late. He said Apple has lagged on hardware innovation, causing 'consumer apathy', and its AI rollout has been glitchy. Apple Intelligence, Apple's AI product, has been limited to incremental features and rather than transformational upgrades.
And it's been more than a year since Apple announced a suite of AI upgrades to its voice assistant Siri – many of which have yet to be released.
'This work [on Siri] needed more time to reach our high-quality bar,' said Craig Federighi, Apple's vice-president of software engineering, during the company's developer conference in June.
Donald Trump's sweeping tariffs have also been a pain point for the company as the US president pushes his desire for manufacturing to boom in the US. The vast majority of Apple's products are made in China, with about 90% of iPhones assembled there, despite recent efforts to shift production elsewhere. Cook said during the company's previous quarterly earnings call that he expected the China tariffs to add $900m to its costs this quarter.
Apple has attempted to pivot, moving more of its manufacturing to other countries such as India and Vietnam. However, this week, Trump announced a rise in tariffs on India, too, up to 25% starting on 1 August.
On Thursday's earnings call, Cook reminded analysts that Apple had pledged to invest $500bn in the US over the next four years and that 'ultimately we will do more in the United States'. He added Apple was 'making good progress on a more personalized Siri' and promised a release next year.
Because of the external and internal pressures, Apple has seen its share price plummet this year. Once the industry leader of the 'Magnificent Seven' – the most valuable publicly traded companies in the world, all American technology giants – Apple boasted the highest-performing stock and biggest market capitalization on the US stock market.
Now its share price is the second-worst performing after Tesla in percentage decline among the seven. Since January, Apple's stock has fallen roughly 15%. In after-hours trading on Thursday, though, the company saw a slight increase of 2.5% in its share price.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pfizer (NYSE:PFE) Reports Upbeat Q2
Pfizer (NYSE:PFE) Reports Upbeat Q2

Yahoo

timea few seconds ago

  • Yahoo

Pfizer (NYSE:PFE) Reports Upbeat Q2

Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q2 CY2025, with sales up 10.3% year on year to $14.65 billion. The company expects the full year's revenue to be around $62.5 billion, close to analysts' estimates. Its non-GAAP profit of $0.78 per share was 35.9% above analysts' consensus estimates. Is now the time to buy Pfizer? Find out in our full research report. Pfizer (PFE) Q2 CY2025 Highlights: Revenue: $14.65 billion vs analyst estimates of $13.58 billion (10.3% year-on-year growth, 7.9% beat) Adjusted EPS: $0.78 vs analyst estimates of $0.57 (35.9% beat) The company reconfirmed its revenue guidance for the full year of $62.5 billion at the midpoint Management raised its full-year Adjusted EPS guidance to $3 at the midpoint, a 3.4% increase Operating Margin: 20.8%, down from 22.4% in the same quarter last year Organic Revenue rose 10% year on year (3% in the same quarter last year) Market Capitalization: $133.8 billion Company Overview With roots dating back to 1849 when two German immigrants opened a fine chemicals business in Brooklyn, Pfizer (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a wide range of diseases and conditions. Revenue Growth A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, Pfizer's sales grew at a decent 8.2% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Pfizer's recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 9.8% over the last two years. Pfizer also reports organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don't accurately reflect its fundamentals. Over the last two years, Pfizer's organic revenue averaged 5.2% year-on-year declines. Because this number is better than its two-year revenue growth, we can see that some mixture of divestitures and foreign exchange rates dampened its headline results. This quarter, Pfizer reported year-on-year revenue growth of 10.3%, and its $14.65 billion of revenue exceeded Wall Street's estimates by 7.9%. Looking ahead, sell-side analysts expect revenue to decline by 3.3% over the next 12 months. Although this projection is better than its two-year trend, it's hard to get excited about a company that is struggling with demand. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Pfizer's operating margin has risen over the last 12 months and averaged 29.9% over the last five years. On top of that, its profitability was top-notch for a healthcare business, showing it's an well-run company with an efficient cost structure. Analyzing the trend in its profitability, Pfizer's operating margin of 25.9% for the trailing 12 months may be around the same as five years ago, but it has decreased by 7.3 percentage points over the last two years. This dynamic unfolded because it failed to adjust its fixed costs while demand fell. This quarter, Pfizer generated an operating margin profit margin of 20.8%, down 1.6 percentage points year on year. This reduction is quite minuscule and indicates the company's overall cost structure has been relatively stable. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Pfizer's EPS grew at an unimpressive 3.3% compounded annual growth rate over the last five years, lower than its 8.2% annualized revenue growth. However, its operating margin didn't change during this time, telling us that non-fundamental factors such as interest and taxes affected its ultimate earnings. Diving into the nuances of Pfizer's earnings can give us a better understanding of its performance. A five-year view shows Pfizer has diluted its shareholders, growing its share count by 1.5%. This has led to lower per share earnings. Taxes and interest expenses can also affect EPS but don't tell us as much about a company's fundamentals. In Q2, Pfizer reported adjusted EPS at $0.78, up from $0.60 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Pfizer's full-year EPS of $3.39 to shrink by 15%. Key Takeaways from Pfizer's Q2 Results We were impressed by how significantly Pfizer blew past analysts' organic revenue expectations this quarter. We were also excited its EPS outperformed Wall Street's estimates by a wide margin. On the other hand, its full-year EPS guidance was in line. Zooming out, we think this was a solid print. The stock traded up 1.9% to $23.99 immediately after reporting. Indeed, Pfizer had a rock-solid quarterly earnings result, but is this stock a good investment here? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Do You Believe in Apple's (AAPL) Long-Term Compelling Value Proposition?
Do You Believe in Apple's (AAPL) Long-Term Compelling Value Proposition?

Yahoo

timea few seconds ago

  • Yahoo

Do You Believe in Apple's (AAPL) Long-Term Compelling Value Proposition?

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its 'RiverPark Large Growth Fund' Q2 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets surged in the second quarter, with the S&P 500 Total Return Index rising 10.94% and the Russell 1000 Growth Index returning 17.84%. The fund also surged in the quarter and returned 15.01%. Continued enthusiasm for artificial intelligence, better-than-expected earnings in several large-cap growth sectors, and improving macroeconomic conditions lifted the markets in the quarter. Growth-focused stocks took the lead once more, with the strongest performance coming from sectors like technology, communication services, and certain areas of consumer discretionary. In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, RiverPark Large Growth Fund highlighted stocks such as Apple Inc. (NASDAQ:AAPL). Apple Inc. (NASDAQ:AAPL) is an American multinational company that designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories. The one-month return of Apple Inc. (NASDAQ:AAPL) was -3.17%, and its shares lost 1.87% of their value over the last 52 weeks. On August 4, 2025, Apple Inc. (NASDAQ:AAPL) stock closed at $203.35 per share, with a market capitalization of $3.018 trillion. RiverPark Large Growth Fund stated the following regarding Apple Inc. (NASDAQ:AAPL) in its second quarter 2025 investor letter: "Apple Inc. (NASDAQ:AAPL): AAPL underperformed in Q2 despite reporting solid results. The company posted revenue of $95.4 billion and EPS of $1.65, with growth in both iPhone and Services. However, investor response to Apple's AI roadmap, unveiled at WWDC in June, was mixed. While Apple introduced several new on-device AI features under its 'Apple Intelligence' initiative, the market viewed the rollout as more incremental compared to peers. A busy sidewalk filled with people using Apple devices like iPhones, iPads and Apple Watches. Apple Inc. (NASDAQ:AAPL) is in 8th position on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 159 hedge fund portfolios held Apple Inc. (NASDAQ:AAPL) at the end of the first quarter, which was 166 in the previous quarter. Apple Inc. (NASDAQ:AAPL) reported revenue of $94 billion in the June quarter, reflecting a 10% year-over-year increase. While we acknowledge the potential of Apple Inc. (NASDAQ:AAPL) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Apple Inc. (NASDAQ:AAPL) and shared the list of AI stocks analysts are watching closely. Aristotle Atlantic Large Cap Growth Strategy also commented on Apple Inc. (NASDAQ:AAPL) in its Q2 2025 investor letter. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

New US-EU trade deal on tariffs ends pharma's geopolitical immunity
New US-EU trade deal on tariffs ends pharma's geopolitical immunity

Yahoo

timea few seconds ago

  • Yahoo

New US-EU trade deal on tariffs ends pharma's geopolitical immunity

For the first time in decades, the pharmaceutical industry has been directly affected by a geopolitical trade negotiation between the US and the EU. On 27 July, the US government announced a 15% tariff on branded pharmaceutical products imported from the EU. Despite the decrease from the original 30% tariff on pharmaceuticals earlier in the year, this disrupts a long-established practice of the exemption of medicines from tariffs due to their importance in public health. The 15% tariff is not expected to happen immediately as implementation will be dependent on a National Security investigation regarding pharmaceutical imports. This trade deal puts the pharmaceutical industry at risk of losing between $13bn and $19bn, with consequences that extend beyond short-term financials. It will force pharmaceutical companies to make a tradeoff between tightening their profit margins and increasing drug prices, with both paths posing a risk to patient access and payer relations. The imposition of tariffs threatens to elevate costs across the pharmaceutical value chain, and could lead to a substantial increase in drug development costs, manufacturing, and distribution, with global supply chains for active pharmaceutical ingredients (APIs), raw materials, and equipment directly exposed. This disruption could create uncertainty in launch planning, particularly for late-stage assets with EU-based manufacturing and production planned for US entry. Companies manufacturing pharmaceutical products in Europe will need to anticipate financial exposure when planning launches in the US due to the unfavourable gross-to-net dynamics, weakened pricing leverage with US payers, and slower commercial uptake as insurers reassess cost-effectiveness due to the tariffs. Research and development budgets are already under pressure, and may be further strained as pharmaceutical companies may have to divert budget to firefight the impact of the tariffs. This could hinder innovation and pipeline investment, reducing the much-needed pace of therapeutic innovation across the industry. Earlier in the year, the US administration did signal tariffs for pharmaceutical imports could become a real possibility; this was met with proactive US investment from leading pharmaceutical companies to onshore manufacturing in the US to reduce exposure. Most recently, in July 2025, Biogen announced a $2bn investment into North Carolina, strengthening its US manufacturing position. Other pharmaceutical companies such as Johnson & Johnson, AstraZeneca, and Eli Lilly have also increased their investment in US manufacturing, with investments of $55bn, $50bn, and $27bn, respectively. Ultimately, the recent US-EU trade deal has increased the level of uncertainty within the pharmaceutical industry, raising concerns about the potential of tariffs increasing past 15% in the future. A once-shielded sector is facing a geopolitical shift, leaving the pharmaceutical industry vulnerable to global volatility. "New US-EU trade deal on tariffs ends pharma's geopolitical immunity" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store